StreetInsider.com News Articles

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 28 Aug 2026 16:15:00 -0400

SAN FRANCISCO, Aug. 28, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on August 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 25,200 shares of its common stock and 5,000 restricted stock units (RSUs) to eleven newly-hired employees under Nektar's 2025 Inducement Plan.

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 28 Aug 2026 16:15:00 -0400

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 28 Aug 2026 16:15:00 -0400

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 28 Aug 2026 16:15:00 -0400

Nektar's atopic dermatitis drug data published in The Lancet

Tue, 25 Aug 2026 08:30:57 -0400

Nektar Therapeutics (Nasdaq: NKTR) announced the publication of Phase 2b trial results for its drug candidate rezpegaldesleukin in The Lancet, covering the 16-week induction period of the REZOLVE-AD study in adults with moderate-to-severe atopic dermatitis.

The global, randomized, double-blind, placebo-controlled trial enrolled 393 biologic- and JAK inhibitor-naive adults across 107 sites in 10 countries. Patients received one of three rezpegaldesleukin dosing regimens or placebo for 16 weeks.

All three dosing arms met the primary endpoint of mean percent reduction in Eczema Area and Severity Index (EASI) from baseline at week 16: 61%, 58%, and 53% for the 24 µg/kg every two weeks,

Nektar's atopic dermatitis drug data published in The Lancet

Tue, 25 Aug 2026 08:30:57 -0400

All three dosing arms met the primary endpoint of mean percent reduction in Eczema Area and Severity Index (EASI) from baseline at week 16: 61%, 58%, and 53% for the 24 µg/kg every two weeks,

Nektar's atopic dermatitis drug data published in The Lancet

Tue, 25 Aug 2026 08:30:57 -0400

All three dosing arms met the primary endpoint of mean percent reduction in Eczema Area and Severity Index (EASI) from baseline at week 16: 61%, 58%, and 53% for the 24 µg/kg every two weeks,

Nektar's atopic dermatitis drug data published in The Lancet

Tue, 25 Aug 2026 08:30:57 -0400

All three dosing arms met the primary endpoint of mean percent reduction in Eczema Area and Severity Index (EASI) from baseline at week 16: 61%, 58%, and 53% for the 24 µg/kg every two weeks,

Nektar's atopic dermatitis drug data published in The Lancet

Tue, 25 Aug 2026 08:30:57 -0400

All three dosing arms met the primary endpoint of mean percent reduction in Eczema Area and Severity Index (EASI) from baseline at week 16: 61%, 58%, and 53% for the 24 µg/kg every two weeks,

Nektar's atopic dermatitis drug data published in The Lancet

Tue, 25 Aug 2026 08:30:57 -0400

All three dosing arms met the primary endpoint of mean percent reduction in Eczema Area and Severity Index (EASI) from baseline at week 16: 61%, 58%, and 53% for the 24 µg/kg every two weeks,

Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

Tue, 25 Aug 2026 08:30:00 -0400